Zentalis Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview

Zentalis Pharmaceuticals

02/05/2025 15:32

Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to show a fall in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

‚ÄčLSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 64 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00‚Äč, above‚Äč its last closing price of $1.45. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.62
-0.71
-0.62
Beat
12.2
Sep. 30 2024
-0.88
-0.91
-0.56
Beat
38.5
Jun. 30 2024
-0.87
-0.84
-1.24
Missed
-47.5‚Äč
Mar. 31 2024
-0.76
-0.77
0.14
Beat
118.3
‚Äč‚ÄčDec. 31 2023
-0.94
-0.92
-0.93
Missed
-1.5
Sep. 30 2023
-0.91
-0.91
-0.79
Beat
13.3‚Äč
Jun. 30 2023
-1.02
-1.04
-1.85
Missed
-78.3
Mar. 31 2023
-0.98
-1.02
-1.07
Missed
-5

This summary was machine generated May 2 at 14:32 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)